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Background. U65, a self-aggregating peptide scaffold, traps fused protein antigens in yeast cells. Conversion to Yeast Cell Particle
(YCP) vaccines by partial removal of surface mannoproteins exposes 𝛽-glucan, mediating efficient uptake by antigen-presenting
cells (APCs). YCP vaccines are inexpensive, capable of rapid large-scale production and have potential for both parenteral and oral
use.Results. YCPprocessing by alkaline hydrolysis exposes up to 20%of the glucan but converts scaffolded antigen and internal yeast
proteins into a common aggregate, preventing selective yeast protein removal. For U65-green fluorescent protein (GFP) or U65-
Apolipoprotein A1 (ApoA1) subcutaneous vaccines, maximal IgG responses in mice required 10% glucan exposure. IgG responses
to yeast proteins were 5-fold lower. Proteolytic mannoprotein removal produced YCPs with only 6% glucan exposure, insufficiently
porous for selective removal of even native yeast proteins. Vaccine efficacy was reduced 10-fold. Current YCP formulations,
therefore, are not suitable for human use but have considerable potential for use in feed animal vaccines. Significantly, a YCP vaccine
expressing a GFP fusion to VP1, the murine polyoma virus major capsid protein, after either oral or subcutaneous administration,
protected mice against an intraperitoneal polyoma virus challenge, reducing viral DNA levels in spleen and liver by >98%.
1. Introduction
Glucan particles (GPs), prepared from the walls of Saccha-
romyces cerevisiae cells, are composed primarily of 𝛽-1,3-D-
glucans (𝛽G) [1, 2]. These are recognized as a fungal cell
wall pathogen-associatedmolecular pattern (PAMP) andGPs
serve as an effective adjuvant for IgG antibody production
when admixed with free antigens [3]. Host phagocytic recep-
tors, including dectin-1 [4] and complement receptor 3 [5],
recognize fungal 𝛽G and this interaction leads to enhanced
cytokine responses by innate immune cells, contributing
to GP adjuvant function [2, 6, 7]. The particles have far
broader efficacy when the antigen is encapsulated inside GPs,
ensuring codelivery of both glucan adjuvant and antigen
to the same endosomal compartment in the same antigen-
presenting cell (APC) [3]. Robust antibody and bothTh1- and
Th17-biased CD4 T cell responses result [3].
Recombinant yeast cells expressing protein antigens
should have similar advantages for codelivery of antigen
and adjuvant, and several reports describe their use as
oral vaccines in feed animals [8]. Saccharomyces cerevisiae
(baker’s yeast) was chosen for antigen expression and YCP
vaccine production since it is generally regarded as safe for
human use (GRAS). In intact yeast cells, however, the highly
porous inner cell wall 𝛽-glucan matrix [3] is masked by
a dense surface mannoprotein layer [9]. Interactions with
mannan receptors provide only inefficient phagocytosis. If
mannoproteins can be effectively removed, eliminating most
of these immunodominant yeast antigens [10] while exposing
glucan and retaining antigen, the resultant Yeast Cell Particles
(YCPs) should constitute an inexpensive, effective vaccine,
capable of rapid production in large quantities and easily
stored as dry powder without refrigeration. YCP vaccines
could potentially be used either parenterally or orally, in
enteric-coated pill form or as a feed additive.
Achievement of this aim poses several requirements.
First, while S. cerevisiae has frequently been used for expres-
sion of foreign proteins, levels are generally low and routine
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Figure 1: YCP vaccine processing and function.
expression levels of at least 5–10% of total protein would be
desirable. Pichia pastoris can be used for much more efficient
protein expression and has been used to produce vaccines
tested inmice [11] and chickens [12] but is not GRAS. Second,
a simple and reproducible extraction method needs to be
developed to process cells into YCP vaccines, exposing a suf-
ficient fraction of cell wall 𝛽G to ensure efficient phagocytosis
and removing most yeast mannoprotein antigens [10]. Third,
this process should allow retention of the desired antigen and,
preferably, should selectively remove internal yeast proteins.
While the outer mannoprotein cell wall layer is relatively
impermeable, the glucanmatrix inGPs is porous to even large
proteins [3]. To ensure antigen retention, therefore, it seemed
likely that it would be necessary to trap the antigen either
linked to a self-assembling polymeric peptide aggregate or
as self-assembling virus-like particles (VLPs). Finally, vaccine
processing (Figure 1) should sterilize the YCP product. As
described below, all objectives have been achieved except for
selective antigen enrichment by removal of internal yeast host
proteins.
While VLPs have been used to present antigenic peptides
in yeast [11], VLP scaffolds may present competing epitopes.
We chose to express antigens as fusions to U65, the weakly
antigenic 65-residue N-terminal fragment of the yeast pro-
tein Ure2p. Polymerization of U65 is self-propagating and
overexpression of U65 is sufficient to induce polymeriza-
tion as cytoplasmic fibrils [13]. It was anticipated that U65
fusions to antigens that do not spontaneously aggregate,
such as green fluorescent protein (GFP), would produce
stable cytoplasmic aggregates with enhanced antigenicity and
improved retention during YCP vaccine preparation. The
lowest percentile rank MHCII binding predicted for U65 in
C57BL/6 mice [14, 15] was 12.3, so U65 epitopes should not
compete with responses to coupled antigens with stronger
epitopes. The U76L scaffold contains 11 additional Ure2p
residues, potentially enhancing scaffold stability, and “L,”
a 9-residue flexible linker allowing independent folding of
U76 and any fused antigen. Predicted MHCII binding is
unchanged. Both U65 and U76L were used as scaffolds for
expression of model antigens GFP (26.9 kDa) and mature
human Apolipoprotein A1 (ApoA1, 28.3 kDa). In this paper,
we demonstrate that YCPs made from both U65- and U76L-
GFP and ApoA1 fusions were highly effective in eliciting
IgG responses in mice and determine the minimal % glucan
exposure sufficient for optimal immune responses.
As a model for the use of YCP vaccines for the prevention
or treatment of infectious disease, we vaccinated mice with
YCPs expressing a GFP fusion to VP1, the major capsid pro-
tein ofmouse polyomavirus (MPyV), which, like the hepatitis
B surface antigen (HBsAg), forms VLPs when expressed in
yeast [16–18], evenwhenC-terminally fused to large antibody
fragments [19]. We demonstrate that the VP1-GFP fusion
assembles into VLP-like structures in the yeast cytoplasm
and that both subcutaneous and oral administration of a
YCP-VP1-GFP vaccine resulted in effective protection against
systemic infection with MPyV.
2. Materials and Methods
2.1. Animals. This study was performed in strict accordance
with the NIH Guide for the Care and Use of Laboratory
Animals. The protocols were approved by the University
of Massachusetts Medical School Institutional Animal Care
and Use Committee (docket A-1778). Mice were observed
daily and euthanized by CO
2
overdose, followed by cervical
dislocation.
2.2. Yeast Strains and Media. Saccharomyces cerevisiae strain
CRY1 has the genotype MAT𝛼 ura3-1 trp1-1 leu2-3,112 his3-
11 can1-100 ade2 GAL SUC [20]. Strain PAP1502 has the
genotype MAT𝛼 ura3-52 trp1::GAL10-GAL4 lys2-801 leu2Δ1
his3Δ200 pep4::HIS3 prb1Δ1.6R can1 GAL and was kindly
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provided by Dr. Pedersen et al. [21]. Yeast extract-glycerol-
peptone (YGP), uracil drop-out (Ura D/O), uracil + leucine
drop-out (Ura + Leu D/O), and uracil + tryptophan drop-out
(Ura + Trp D/O) media were prepared as described in Cold
Spring Harbor protocols (Cold Spring Harbor Press).
2.3. Antisera and Antiglucan FACS Assay for Glucan Exposure.
Anti-𝛽-1,3-glucan antibody murine monoclonal IgG kappa
was purchased from Biosupplies, Australia. For analysis of
glucan exposure, yeast cells, YCPs, or glucan particles (4
× 107) were washed in phosphate-buffered saline (PBS),
suspended in 500 𝜇L PBS + 1% bovine serum albumin (BSA)
for 30min at 23∘C, and then suspended in 100 𝜇L anti-𝛽-
1,3-glucan mouse IgG diluted 1 to 100 in PBS + 1% BSA.
After 60min at 23∘C, cells were washed three times in PBS
+ 1% BSA and suspended in R-phycoerythrin-conjugated
polyclonal goat anti-mouse IgG (Sigma-Aldrich) diluted 1
to 50 in PBS + 1% BSA. After 60min, cells were washed
three times in PBS + 1% BSA and analyzed by fluorescence-
activated cell sorting (FACS).
2.4. Concanavalin A Assays for Exposed Mannan. Cells
and YCPs were incubated with various dilutions of Con-
canavalin A-FITC (fluorescein isothiocyanate) conjugate
(Sigma-Aldrich) or ConcanavalinAlexa Fluor 488 (Life Tech-
nologies) in PBS. After 5min at 23∘C, cells were washed three
times in PBS and assayed by fluorescent microscopy (FITC)
or by measurement of the 488/519-excitation/emission fluo-
rescence signal. GPs were used as negative controls and YCPs
were compared to untreated cells with 100% normal mannan
exposure.
2.5. 3T3-D1 Cell Phagocytosis. NIH 3T3-D1 cells [4] were
plated at 2.5× 104 cells/well in 24-well plates in 0.5mLDMEM
(Invitrogen) + 10% fetal calf serum (Gibco) + 1% penicillin-
streptomycin (Gibco) and incubated overnight at 37∘C, 5%
CO
2
, producing 5 × 104 cells/well. Wells were washed with
PBS (Gibco) and 500𝜇L DMEM-minus serum was added.
Cells or YCPs were washed in PBS, diluted to 5 × 106/mL, and
50𝜇L was added to wells to achieve a ratio of 5 particles/cell.
After incubation for 1.5 hours, cells were washed twice with
PBS, fixed in 1% formalin, and stained with Congo red
(Sigma-Aldrich), which binds to yeast glucan. Cells were then
scored microscopically at 200x magnification for evidence
of yeast particle phagocytosis by detection of GFP and
coincident staining with Congo red. Because untreated yeast
cells adhere to 3T3 cell surfaces, backgrounds were high
(25%) and only responses >50% were scored as positive.
2.6. Plasmid Constructs
pB4-VP1. The HBsAg open-reading frame (ORF) and the
preceding pGAL/pGDH promoter were cloned by PCR from
S. carlsbergensis strain ATCC 20705 total DNA using the
primers 5󸀠 GGG AAG CTT CTC TTT GGA ACT TTC AG
and 5󸀠 GGG AGA TCT CAA TAA GAG CGA CCT CAT
GC. The product was cloned as a 1450 bp HindIII to BglII
fragment in p-M28 LEU2 [22], producing pB4-HBs.The VP1
capsid protein gene ofMPyV, nominally strainA2,was cloned
by PCR using as template a tissue culture supernatant from
infected cells and the primers 5󸀠 C ACC AAG AAC TTA
GTT TCG AAT AAA CAC ACA TAA ACA AAC AAC TCG
AGG AAG ATG GCC CCC AAA AGA AAA AGC and 5󸀠
TTG ATC TAT CGA TTT CAA TTC AAT TCA ATT TAT
TTC CCGGAT CGAAGATCTCAT TAA TTT CCA GGA
AAT ACA GTC TTT G. The flanking sequences are homol-
ogous to the ends of the pGDH and tPGK segments in pB4-
HBs. pB4-HBs was cut with XbaI (at codon 31 in HBsAg)
and BglII and the purified vector fragment and PCR product
were cotransformed into leu2 yeast strain CRY1. Sequencing
confirmed that Leu+ isolates carried pB4-VP1 in which
the VPI open-reading frame replaces HBsAg between the
pGAL/pGDH promoter and the tPGK terminator. Sequence
analysis showed that the cloned VP1 open-reading frame is
precisely that from strain BG (GenBank AF442959).
pB4-GFP, pGUL2-GFP, pGUL2-VP1, and pGUL2-VP1-GFP. In
this paper, GFP refers to GFPbex1, a form of GFP with 25-
fold enhanced fluorescence [23]. GFPbex1 was cloned by PCR
from pDJ388 [23] using primers 5󸀠 G CAG GGC TCG AGC
ATG AGT AAA GGA GAA GAA CTT TTC ACT G and
5󸀠 GGA TCG GAG ATC TTA TTT GTA TAG TTC ATC
CAT GCC ATG and cloned into pB4-VP1, replacing VP1
and producing pB4-GFP. The GFP-tPGK fragment of pB4-
GFP was inserted into the expression cassette of pEMBLyex4
(EMBL, Heidelberg). The CYC1-GFP fragment was then
replaced with the GAL1-GDH promoter and GFP segments
from pB4-GFP producing pGUL2-GFP. The GFP fragment
in pGUL2-GFP was replaced with the VP1 segment of pB4-
VP1 producing pGUL2-VP1. The GDH fragment of pGUL2-
GFP was replaced with the GDH-VP1 segment of pB4-VP1
producing pGUL2-VP1-GFP. As illustrated in Figure 2, all
pGUL2 constructs comprise two copies of the bidirectional
GAL1/10Gal4p binding sites (in inverted orientations).These
precede the GDH promoter fragment and the expressed
reading frames and are followed by two tPGK terminators.
The sequence of the expression cassette in pGUL2-VP1-GFP,
including the BG strain VP1 gene, is shown in Figure 3.
pGUL2-U65- and U76L-GFP. The 65-codon N-terminal
fragment of the yeast URE2 protein Ure2p, including the
native NotI site at its C-terminus, was cloned by PCR using
pH324A [13] as template and the primers 5󸀠 GGG TAG CCT
CGAGGATCCGTCGACAGAATG ATG AAT AAC AAC
GGC AAC and 5󸀠 GCT GCT GAA TTC TCG AGC GGC
CGC TGT TAT TGT TTT G. The product was cut with
SalI and XhoI and cloned into pGUL2-GFP, cut with
XhoI, and hydrolyzed with CIP, producing pGUL2-U65-
GFP. Sequence analysis identified clones with 195 bp inserts
corresponding to single U65 inserts linked in-frame to
GFP (Figure 4). The 76-codon N-terminal fragment of
Ure2p was cloned using pH324A [13] as template and the
primers 5󸀠 GG GTA GCG TCG ACA CTA GTC AGA
ATG ATG AAT AAC AAC GGC AAC and 5󸀠 CAG GAC
CCT CGA GTC TAG ACC GGA AGA GCC ACC AGA
GGA ACC GCC ATT ATT CTC GTT ATC ATT ATT TTG.
The product was cut with Sal1 and Xho1 enzymes and
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Figure 2: The pGUL2-VP1-GFP expression vector showing the expression cassette and its induction by galactose-induced expression of
Gal4p, augmented by overexpression from the GAL1 UAS-driven GAL4 gene inserted at TRP1 in the strain PAP1502 chromosome.
GATCAAAAATCATCGCTTCGCTGATTAATTACCCCAGAAATAAGGCTAAAAAACTAATCGCATTATCATCCTATGGTTGTTAATTTGATTCGTTCATTTGAAGGTTTGTGGGGCCA
GGTTACTGCCAATTTTTCCTCTTCATAACCATAAAAGCTAGTATTGTAGAATCTTTATTGTTCGGAGCAGTGCGGCGCGAGGCACATCTGCGTTTCAGGAACGCGACCGGTGAAG
ACGAGGACGCACGGAGGAGAGTCTTCCTTCGGAGGGCTGTCACCCGCTCGGCGGCTTCTAATCCGTACTTCAATATAGCAATGAGCAGTTAAGCGTATTACTGAAAGTTCCAAA
GAGAAGGTTTTTTTAGGCTAATCGACCTCGACTGCTAGCTCAGCTTCTCTTTGGAACTTTCAGTAATACGCTTAACTGCTCATTGCTATATTGAAGTACGGATTAGAAGCCGCCGA
GCGGGTGACAGCCCTCCGAAGGAAGACTCTCCTCCGTGCGTCCTCGTCTTCACCGGTCGCGTTCCTGAAACGCAGATGTGCCTCGCGCCGCACTGCTCCGAACAATAAAGATTCT
ACAATACTAGCTTTTATGGTTATGAAGAGGAAAAATTGGCAGTAACCTGGCCCCACAAACCTTCAAATGAACGAATCAAATTAACAACCATAGGATGATAATGCGATTAGTTTTTT
AGCCTTATTTCTGGGGTAATTAATCAGCGAAGCGATGATTTTTGATCGTCGACGGATCCCCAGCTTGTCTCTTAGCGCAACTACAGAGAACAGGGGCACAAACAGGCAAAAAAC
GGGCACAACCTCAATGGAGTGATGCAACCTGCCTGGAGTAAATGATGACACAAGGCAATTGACCCACGCATGTATCTATCTCATTTTCTTACACCTTCTATTACCTTCTGCTCTCTC
TGATTTGGAAAAAGCTGAAAAAAAAGGTTGAAACCAGTTCCCTGAAATTATTCCCCTACTTGACTAATAAGTATATAAAGACGGTAGGTATTGATTGTAATTCTGTAAATCTATTT
CTTAAACTTCTTAAATTCTACTTTTATAGTTAGTCTTTTTTTTAGTTTTAAAACACCAAGAACTTAGTTTCGAATAAACACACATAAACAAACAA ATGGCCCCCAAACTCGAGGAAG
AGAAAAAGCGGCGTCTCTAAATGCGAGACAAAATGTACAAAGGCCTGTCCAAGACCCGCACCCGTTCCCAAACTGCTTATTAAAGGGGGTATGGAGGTGCTGGACCTTGTGACA
GGGCCAGACAGTGTGACAGAAATAGAAGCTTTTCTGAACCCCAGAATGGGGCAGCCACCCACCCCTGAAAGCCTAACAGAGGGAGGGCAATACTATGGTTGGAGCAGAGGGA
TTAATTTGGCTACATCAGATACAGAGGATTCCCCAGAAAATAATACACTTCCCACATGGAGTATGGCAAAGCTCCAGCTTCCCATGCTCAATGAGGACCTCACCTGTGACACCCTA
CAAATGTGGGAGGCAGTCTCAGTGAAAACCGAGGTGGTGGGCTCTGGCTCACTGTTAGATGTGCATGGGTTCAACAAACCCACAGATACAGTAAACACAAAAGGAATTTCCACT
CCAGTGGAAGGCAGCCAATATCATGTGTTTGCTGTGGGCGGGGAACCGCTTGACCTCCAGGGACTTGTGACAGATGCCAGAACAAAATACAAGGAAGAAGGGGTAGTAACAAT
CAAAACAATCACAAAGAAGGACATGGTCAACAAAGACCAAGTCCTGAATCCAATTAGCAAGGCCAAGCTGGATAAGGACGGAATGTATCCAGTTGAAATCTGGCATCCAGATCC
AGCAAAAAATGAGAACACAAGGTACTTTGGCAATTACACTGGAGGCACAACAACTCCACCCGTCCTGCAGTTCACAAACACCCTGACAACTGTGCTCCTAGATGAAAATGGAGTT
GGGCCCCTCTGTAAAGGAGAGGGCCTATACCTCTCCTGTGTAGATATAATGGGCTGGAGAGTTACAAGAAACTATGATGTCCATCACTGGAGAGGGCTTCCCAGATATTTCAAA
ATCACCCTGAGAAAAAGATGGGTCAAAAATCCCTATCCCATGGCCTCCCTCATAAGTTCCCTTTTCAACAACATGCTCCCCCAAGTGCAGGGCCAACCCATGGAAGGGGAGAACA
CCCAGGTAGAGGAGGTTAGAGTGTATGATGGGACTGAACCTGTACCGGGGGACCCTGATATGACGCGCTATGTTGACCGCTTTGGAAAAACAAAGACTGTATTTCCTGGTCTAG
AGTCGAGCATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTG
ATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCACTTATGGTGTTCAATGCTTTTCAAGATACCC
AGATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCAA
GTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTATAC
ATCATGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGC
GATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCTGCTGG
GATTACACATGGCATGGATGAACTATACAAATAAGATCTTCGATCCGGGAAATAAATTGAATTGAATTGAAATCGATAGATCAATTTTTTTCTTTTCTCTTTCCCCATCCTTTACGC
TAAAATAATAGTTTATTTTATTTTTTGAATATTTTTTATTTATATACGTATATATAGACTATTATTTACTTTTAATAGATTATTAAGATTTTTATTAAAAAAAAATTCGTCCCTCTTTTTA
ATGCCTTTTATGCAGTTTTTTTTTCCCATTCGATATTTCTATGTTCGGGTTTCAGCGTATTTTAAGTTTAATAACTCGAAAATTCTGCGTTTCGAAAAAGCTGGTCGACGGAATTCGC
GGGGGATCTCCCATGTCTCTACTGGTGGTGGTGCTTCTTTGGAATTATTGGAAGGTAAGGAATTGCCAGGTGTTGCTTTCTTATCCGAAAAGAAATAAATTGAATTGAATTGAAA
TCGTAGATCAATTTTTTTCTTTTCTCTTTCCCCATCCTTTACGCTAAAATAATAGTTTATTTTATTTTTTGAATATTTTTTATTTATATACGTATATATAGACTATTATTTATCTTTTAATG
ATTATTAAGATTTTTATTAAAAAAAAATTCGCTCCTCTTTTAATGCCTTTATGCAGTTTTTTTTTCCCATTCGATATTTCTATGTTCGGGTTTCAGCGTATTTTAAGTTTAATAACTCGA
AAATTCTGCGTTCGTTAAAGCTTATGATCC 
Figure 3: Sequence of the pGUL2-VP1-GFP expression cassette showing the duplicated upstream GAL1/10 UAS fragments (blue), the
first (357 bp) in GAL1-GAL10 orientation and the second (353 bp) inverted. These are followed by the pGDH fragment (388 bp, also blue)
completing the hybrid promoter. The reading frame for strain BG VP1 (1152 bp, red) is fused to GFPbex (915 bp, orange) and the two tPGK
terminator segments (314 and 381 bp, blue) complete the cassette, as shown schematically in Figure 2.
cloned into pGUL2-GFP, cut with Xho1, and hydrolyzed with
CIP. Sequence analysis identified clones with 255 bp inserts
corresponding to single U76L inserts linked in-frame to GFP.
U76 andGFP are separated by the 9-residue L (GGSSGGSSG)
linker segment (Figure 4).
pGUL2-U65-ApoA1 and U76L-ApoA1. The mature human
Apolipoprotein A1 (ApoA1) gene was constructed by Gen-
eArt Inc. with codons optimized for expression in yeast and
cloned as an XhoI to BglII fragment into pGUL2-U65-GFP,
cut with the same enzymes, replacing the GFP segment and
producing pGUL2-U65-ApoA1. Insertion of the same ApoA1
fragment into pGUL2-U76L-GFP produced pGUL2-U76L-
ApoA1. Insertion of an XbaI linker between the U65 and GFP
components of pGUL2-U65-GFP and insertion of the ApoA1
gene as an XhoI to XbaI fragment produced pGUL2-U65-
ApoA1-GFP. pGUL2-U76L-GFP was converted to pGUL2-
U76L-ApoA1-GFP by the same procedure.
2.7. Protein Expression in pGUL2 Transformants of Strain
PAP1502. pGUL2 vectors (Figures 2 and 3) carry bothURA3
and leu2dmarkers.While selection for URA3 functionmain-
tains 10–20 plasmid copies/cell, normal for YEp vectors with
2-micron replicative functions, selection for leu2d function
Journal of Immunology Research 5
U65-GFP
1
ATG ATG AAT AAC AAC GGC AAC CAA GTG TCG AAT CTC TCC AAT GCG CTC CGT CAA GTA 
Met Asn Asn Asn Gly Asn Gln Val Ser Asn Leu Ser Asn Ala Leu Arg Gln Val 
20
AAC ATA GGA AAC AGG AAC AGT AAT ACA ACC ACC GAT CAA AGT AAT ATA AAT TTT GAA 
Asn Asn Gly Asn Arg Asn Ser Asn Thr Thr Thr Asp Gln Ser Asn Ile Asn Phe Glu
39
TTT TCA ACA GGT GTA AAT AAT AAT AAT AAT AAC AAT AGC AGT AGT AAT AAC AAT AAT 
Phe Ser Thr Gly Val Asn Asn Asn Asn Asn Asn Asn Ser Ser Ser Asn Asn Asn Asn
58 NotI 65 XhoI
GTT CAA AAC AAT AAC AGC GGC CGC TCG AGC ATG AGT AAA   
Val Gln Asn Asn Asn Ser Gly Arg Ser Ser Met Ser Lys
U76L-GFP
NotI Linker
---AGC GGC CGC AAT GGT AGC CAA AAT AAT GAT AAC GAG AAT AAT GGC GGT TCC TCT
---Ser Gly Arg Asn Gly Ser Gln Asn Asn Asp Asn Glu Asn Asn Gly Gly Ser Ser
XbaI XhoI GFP
GGT GGC TCT TCC GGT CTA GAC TCG AGC ATG AGT AAA   
Gly Gly Ser Ser Gly Leu Asp Ser Ser Met Ser Lys
Met 
GFP →
65 76 L
Figure 4: Sequences of the U65 and U76L scaffold fragments showing the XhoI sites (blue) for fusions to GFP (red) just upstream of the NotI
site in U65 and following codon 76 and the 9-residue flexible linker (orange) in U76L.
requires at least 10-fold higher copy number, potentially
allowing a similar increase in plasmid-encoded expression.
All cultures were grown at 30∘C. Transformants were selected
on Ura D/O plates, cloned on these plates, and grown in Ura
+ Trp D/O medium with 2% sucrose as carbon source. The
absence of Trp ensured maintenance of the pGAL1-driven
GAL4 gene integrated with TRP1 at trp1 (Figure 2) [21].
Under galactose induction, autoinduced Gal4p expression
diverts most of the transcription/translation machinery to
GAL genes. Cell division ceases, plasmid selection becomes
irrelevant, and nonselective GP medium can be used to
support galactose-induced expression. Expression of pGUL2-
GFP protein fusions under leu2d selection then approaches
30% of total protein. Stationary phase cells were diluted 1
to 100 in prewarmed Leu + Trp D/O medium with 0.6%
sucrose and 2% glycerol (500mL) and grown in 3-liter
fluted Fernbach flasks with high aeration for 18–20 hours, by
which time they should be fully derepressed for GAL gene
expression, reaching 6 × 107 cells/mL. Cells were then rapidly
harvested by centrifugation at 20∘C, suspended in 250mL of
YGP medium at 30∘C, and, after 60 minutes, induced by the
addition of 27mL of 20% galactose. Cell numbers remained
constant. Cells were harvested after 18–22 hours.
2.8. SDS-PAGE and Determination of Expressed Protein Con-
tent by Stain or GFP Fluorescence. Cells and YCPs (1.2 ×
107) in 0.2mL buffer A (50mM Tris-HCl, pH 7.6, 150mM
NaCl, 10mM NaN
3
, 10mM KF, and 2.5mM EDTA) were
completely broken by vortexing with glass beads. Total
proteins in these samples, or soluble proteins after removal
of cell wall fragments by brief centrifugation at 3,000×g
(3 to 12 𝜇L), were analyzed by 10% SDS-PAGE. Gels were
stained with Coomassie blue and imaged using a Kodak
Gel logic 200 illuminator. Exposures were adjusted to give
a range of images representative of band densities. These
were quantitated using Photoshop, giving the ratio of pixel
density in individual bands to that in the entire gel lane.
Pixel density at the same location in a lane on the same
gel showing proteins from equal cell numbers expressing a
protein with different mobility was subtracted.The difference
is the % of total protein represented by the band of interest.
Protein content of U65-GFP after purification from broken
cells provided a standard for fluorescence analysis of GFP
content, measured using aMolecular Devicesmicrotiter plate
reader (490 nm excitation, 520 nm emission). Fluorescence
intensities of unbroken and broken cells were essentially
identical, allowing determination of GFP fusion protein
expression by measurement of culture fluorescence.
2.9. High pH YCP Vaccine Processing. Cells (6 × 1010) were
washed by suspension in 500mL sterile 0.9% saline and
then three times in 60mL saline. Cells, vigorously stirred
at 109/mL in 50mL saline, were warmed to 45∘C and then
rapidly adjusted to pH 11.5–12 by addition of 4M NaOH.
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The initial pH under standard conditions was 11.9. Additional
4M NaOH was added, mostly in the first 3min, to prevent
the pH from falling more than 0.2 units below the initial
pH to overcome the buffering resulting from exposure of
intracellular components, principally phosphate esters (PKa3
12.3). After 12min, 1mL of 1M Tris-HCl was added, lowering
the pH to about 9. Cells were then transferred to an ice/water
bath, centrifuged at 4∘C, washed four times in 50mL cold
PBS, and stored at −20∘C in 5mL aliquots (2.4 × 109/mL).
2.10. Ficin YCP Processing. PAP1502 cells (4.8 × 109/mL) were
shaken at 37∘C in 25mL PBS + 10mM EDTA, 4mM azide,
1% 𝛽-mercaptoethanol, and 8mg/mL ficin (Sigma). After
30min at 37∘C, cells were washed three times at 23∘C with
saline, twice with 25mL 0.02MNaOH (pH of the suspension
was 12), again with saline, then with PBS + 50𝜇M TPCK
(Sigma) to inactivate residual ficin, and finally three times
with PBS. Ficin YCPs were stored at −20∘C in PBS in 5mL
aliquots (2.4 × 109/mL).
2.11. YCP U76L-ApoA1 Vaccination Protocol. A single group
of four C57BL/6 female 6-week-old mice were vaccinated
subcutaneously with 100 𝜇L (4 × 108) YCPs containing about
120𝜇g U76L-ApoA1 (90𝜇g ApoA1) on days 0, 14, 28, and 42
and mice were bled on days 13, 27, 41, and 55. IgG responses
to ApoA1 were determined by ELISA using wells coated with
0.1 𝜇g of ApoA1, a gift from Capricorn Products LLC. Wells
coated with 0.1𝜇g of purified U76L-GFP were used to test
IgG responses to theU76L scaffold, andwells coated with 1 𝜇g
of total proteins from PAP1502 cells expressing pGUL2-VP1
were used to test IgG responses to total yeast proteins.
2.12. U65-GFP Vaccination Protocol. 25 C57BL/6 female 6-
week-old mice were divided into five groups of five as
described below. All mice were vaccinated subcutaneously on
days 0, 14, 28, and 42 and bled on days 13, 27, 41, and 55.
Sera were assayed for IgG responses by ELISA using wells
coated with 0.1𝜇g recombinant GST-GFP purified from E.
coli. Mice other than Group E were vaccinated with 100 𝜇L
YCPs (4 × 109/mL), containing about 110 𝜇g U65-GFP (90𝜇g
GFP). Group A mice were vaccinated with U65-GFP YCPs
extracted at 45∘C, pH 11.9–11.7. Group Bmice were vaccinated
with YCPs extracted at 45∘C at pH 11.6–11.4. Group C mice
were vaccinated with YCPs extracted at 45∘C at pH 11.5–11.3.
Group D mice were vaccinated with YCPs processed using
ficin. GroupEmicewere vaccinated at two separate sites, each
with 100 𝜇L of the same U65-GFP YCP vaccine used for mice
in Group A, but at 2x concentration (8 × 109/mL), so that the
total dose was 4x the Group A dose.
2.13. VP1-GFP YCP Oral and Subcutaneous Vaccination
and Viral Challenge Protocols. Groups of five six-week-old
C57BL/6 female mice were immunized with the YCP-VP1-
GFP vaccine. GroupAmice were immunized subcutaneously
on days 1, 15, 29, 43, and 57 with 1.25 × 108 YCPs in 50 𝜇L
PBS containing about 800𝜇g total protein, of which 96 𝜇g
(12%) was the VPI-GFP fusion protein, 36 𝜇g was GFP, and
60 𝜇g was VP1. Oral dosage by gavage (Groups B and C)
was administered to mice fasted for three hours, both before
and after dosage, and in the presence of bicarbonate to
suppress stomach acidity [24]. Group Bmice were vaccinated
by oral gavage with 5 × 108 YCPs in 80 𝜇L PBS containing
about 400𝜇g VPI-GFP fusion protein (low dose, 250 𝜇g
VP1) and Group C mice received 1.25 × 109 YCPs in 250 𝜇L
PBS containing 960𝜇g VPI-GFP fusion protein (high dose,
600𝜇gVP1). GroupDmicewere unvaccinated controls.Mice
were orally vaccinated on three consecutive days (days 1, 2,
and 3; 15, 16, and 17; etc.) at two-week intervals and so received
either 12.5 or 30 times the subcutaneous dose. One mouse in
each group was prebled on day 0 to provide preimmune sera.
Micewere bled ondays 14, 28, 42, 56, and 71 through tail veins.
Stools were collected for IgA analysis on day 56. Mice were
challenged intraperitoneally with 106 plaque-forming units
(pfu) of polyomavirus strain A2 in ∼100𝜇L volume on day
72 and were sacrificed for analyses of viral DNA content on
day 77.
2.14. ELISA to Measure Antigen-Specific IgG Titers. MPyV
VP1-specific ELISAs were conducted as previously described
[25]. Briefly, recombinant VP1 protein produced in E. coli
and highly purified (kind gift from Dr. Robert Garcea,
University of Colorado, Boulder) was used to coat 96-well
plates (at 0.1 𝜇g/mL in carbonate buffer, 50 ng/well). Purified
recombinant GST-GFP fusion was used to coat wells used to
assay responses to GFP. Bound antibody was detected using
biotin-conjugated goat antibodies specific for mouse IgG and
streptavidin-conjugated HRP (Vector Laboratories). ELISA
plates were developed using BD OptEIA TMB Substrate
Set (BD Pharmingen), and reactions were stopped with 2N
sulfuric acid. Optical densities were read at 450 nm using
a Molecular Probes microplate reader and analyzed using
Softmax software. ApoA1-specific, GFP-specific, and yeast
protein-specific assays used plates coated with 0.1𝜇g/well
ApoA1 or GFP or 1 𝜇g/well total yeast proteins from strain
PAP1502 cells, respectively. IgG titers are expressed as recip-
rocals of the highest serum dilutions that gave responses
twofold above the negative controls plus standard deviation.
2.15. Quantitative PCR (qPCR) to Measure MPyV DNA
Genome Copy Number. DNA was prepared from organ
homogenates by digestion with proteinase K (Sigma) at 55∘C
overnight, followed by phenol extraction and RNase A treat-
ment (10 u/mL, Promega) [25]. A 50 𝜇L PCR amplification
mix contained 0.5U of Taq polymerase (Promega), 0.66U
SYBR-Green (Molecular Probes), 0.1mM each of forward
and reverse primer (Invitrogen), 5 nM fluorescein (Bio-Rad),
and 1 𝜇g of the DNA sample. Primers were as follows: 𝛽-
actin forward CGA GGC CCA GAG CAA GAG AG; 𝛽-
actin reverse CGG TTG GCC TTA GGG TTC AG; MPyV
VP1 forward CCC CCG GTA CAG GTT CAG TCC CAT
CAT; VP1 reverse GGC ACA ACA GCT CCA CCC GTC
CTG CAG. Negative controls for PCR amplification of viral
DNA included no DNA and DNA from uninfected mouse
organs. Serial dilutions of DNA from uninfected mouse
organs (1mg–31 ng) were used to generate a 𝛽-actin standard
curve. For MPyV standard curve, a plasmid containing the
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Figure 5: (a) SDS-PAGE of proteins from cells expressing the following: Lane 1, VP1-GFP (70 kDa, arrow); Lanes 2–4, U76L-GFP (36.2 kDa,
arrow, loads of 12, 6, and 3 𝜇L, resp.); Lanes 5 and 6, U65-GFP (34.1 kDa, arrow, independent cultures). (b) Fluorescence microscopy of cells
expressing U65-GFP. Cell wall glucan is stained by Congo red. (c) pH 11.5 YCPs.
VP1 coding sequences in dilutions from 26108 to 20 copies
was mixed with 1𝜇g of DNA from uninfected mouse organs.
Reactions were run in duplicate and MPyV copy number
data were normalized to 𝛽-actin gene copies, reflecting the
amount of mouse genomic DNA present, and the results
were expressed as MPyV genome copies/𝜇g organ DNA.
Statistical significance was determined by unpaired Student’s
𝑡-test, assuming unequal variances. A 𝑝 value of <0.05 was
considered statistically significant.
3. Results
3.1. High Level Expression of U65-GFP and ApoA1 Fusions
Generates Cytoplasmic Inclusions. pGUL2-antigen transfor-
mants of strain PAP1502 were used for all YCP vaccine
production. Optimal expression of VP1-GFP (70 kDa), U65-
GFP (34.1 kDa), and U76L-GFP (36.2 kD) was 30, 26, and
23% of total protein, respectively. These were easily visible
on stained SDS gels of total proteins (Figure 5(a)). The
background from overlapping yeast protein bands was sub-
tracted in measuring fusion protein expression by stained
band intensity. GFP fluorescence was identical in intact and
broken cells expressing GFP or GFP fusions, allowing the use
of culture sample fluorescence as an independent measure
of expression. Results from stained band intensities were
consistent with the far more precise fluorescence data.
TheU65 and U76L fusions formed single large aggregates
in cells, visible by fluorescent microscopy (Figure 5(b)) and
these were highly enriched in 16,000×g pellet fractions
(Figure 6(a), Lanes 2, 5, 8, 11, and 14) derived from 3,000×g
supernatants (Lanes 1, 4, 7, 10, and 13) of broken cells. Most
yeast proteins remain in the 16,000×g supernatants (Lanes
3, 6, 9, 12, and 15). Cultures of independent U76L-ApoA1-
GFP transformants (Lanes 4–9) illustrate the reproducibility
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Figure 6: (a) SDS-PAGE of proteins from cells expressing the
following: Lanes 1–3, U76L-ApoA1 (37.7 kDa, arrow); Lanes 4–6
and 7–9, U76L-ApoA1-GFP (64.6 kDa, arrow); Lanes 10–12, U65-
ApoA1-GFP (62.5 kDa, arrow); and Lanes 13–15,U65-GFP (34.1 kDa,
arrow). For each set, the first lane is 3,000×g supernatant, the second
is 16,000×g pellet, and the third is 16,000×g supernatant. (b) SDS-
PAGE. Lanes 1, 4, and 8 are total proteins, Lanes 2, 5, and 9 are
200,000×g pellets, and Lanes 3, 6, and 7 are 200,000×g super-
natants. Lanes 1–3 and 7–9, cells and YCPs, respectively, expressing
U65-ApoA1 (35.6 kDa, arrow). Lanes 4–6, YCPs expressing U76L-
ApoA1 (37.7 kDa, arrow).
of the expression data. After breaking cells in the presence of
40mM octyl glucoside to solubilize membrane proteins and
repeated rounds of differential centrifugation, SDS-PAGE
analysis showed the GFP and ApoA1 fusion proteins with no
visible contamination by yeast proteins (not shown). Electron
microscopy of these purified fractions showed the linear fib-
rillar matrix characteristic of Ure2p aggregates (Figure 7(b)).
3.2. U65 and U76L Fusions Form an Aggregate with Yeast
Proteins in pH 11.9 YCPs. The simplest and most scalable
procedure for converting yeast cells to YCP vaccines is by
extraction of mannoproteins for 12min at 45∘C at pH 11.9–
11.7, a milder form of the process used for GP production [1].
Cells were rapidly killed and sterilized by this treatment.
After breakage of cells expressing U65-ApoA1 and pel-
leting wall fragments at 3000×g, total proteins are shown
in Figure 6(b), lane 1. All of the U65-ApoA1 was found in
the 200,000×g pellet from this fraction (lane 2) while most
of the soluble yeast proteins remained in the 200,000×g
supernatant (lane 3). Total proteins in broken U76L-ApoA1
and U65-ApoA1 YCPs processed under standard conditions
are shown in lanes 4 and 8, respectively. All proteins were
found in the 200,000×g pellet fraction (lanes 5 and 9). Little if
any remained in the 200,000×g supernatant fractions (lanes
6 and 7). U65-GFP, U76L-GFP, and U65-ApoA1-GFP fusions
fractionated similarly after pH 11.9 YCP processing (not
shown).ThusU65 andU76L fusions form an insoluble aggre-
gate with internal yeast proteins in pH 11.9-treated YCPs.
Removal of yeast cell membranes should allow elution of
any soluble proteins through the exposed porous glucan shell.
U65 and U76L fusions were retained in YCPs at 37∘C in PBS
in the presence of 1% triton X100 and 1%𝛽-mercaptoethanol.
Addition of 0.1% sarkosyl solubilized small quantities of low
molecular weight yeast proteins. At higher sarkosyl levels,
all proteins became progressively more soluble (not shown).
Thus, yeast protein aggregates in YCPs could not be solubi-
lized by nonionic detergents and the zwitterionic detergent
disrupted both scaffolded antigens and protein aggregates.
Denaturants (urea, guanidine hydrochloride), like detergents,
failed to selectively solubilize host proteins.
3.3. Optimizing Glucan Exposure during YCP Preparation.
Glucan exposure on cells and YCPs was measured by binding
of anti-𝛽G monoclonal antibody using FACS analysis. As
shown in Figure 8(a), purified GPs with fully exposed glucan
had amean fluorescence intensity (MFI) of∼1,500. Binding to
YGMPs, heterogeneous glucan particles retaining a fraction
of mannan [26], produced a broader fluorescence peak
extending from about 400 to 1,500, equivalent to 25–100%
of GP MFI (Figure 8(b)). Binding to untreated PAP1502 cells
was very low (MFI 3-4), less than control GP samples stained
with secondary antibody only (MFI 10, Figure 8(a)). YCPs
exhibited sharp anti-𝛽Gbinding peaks, indicating uniformity
of mannan removal, as shown in Figure 8(b) for YCP-VP1-
GFP (see below) made under standard pH 11.9 conditions.
MFI for YCPs made at pH 11.9 varied between 12 and 15% of
binding to GPs.
U65-GFP YCPs were made by 12min hydrolysis at 45∘C
using a range of initial pH values, hoping to find conditions
compatible with both glucan exposure and retention of
protein solubility. Binding to YCPs extracted at pH 12 to 11.8
was 20% of binding to GPs. At pH 11.9 to 11.7, binding was
14%. At pH 11.6 to 11.4, binding was 10%, and, at pH 11.5
to 11.3, binding was 6-7%. Thus, reduction in the stringency
of alkaline hydrolysis produced a corresponding decrease in
glucan exposure. However, even processing at pH 11.5 to 11.3
converted the majority of yeast proteins and the antigen into
a common aggregate present in the 16,000×g pellet (Figure 9,
Lane 8), although about 30% did remain soluble (Lane 9).
3.4. GFP Is Effectively Trapped by U65 and U76L Scaffolds
at pH 11.5. While fluorescence of GFPbex1 is remarkably
stable at pH 7 to 11.4 at 23∘C, fluorescence is completely lost
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Figure 7: Negative-stain electron microscopy of (a) VP1-GFP VLPs and (b) aggregated fibrils of U65-GFP. The bar indicates 50 nm.
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Figure 8: Anti-𝛽-1,3-D-glucan binding (FACS). (a) Binding toGPs definesMFI (mean fluorescence intensity) of pure glucan.Control, binding
to GPs using secondary antibody only. (b) Cells, untreated PAP1502 cells. YCPs, binding to pH 11.9 VP1-GFP YCPs. YGMPs, cell wall particles
from which most mannan has been removed.
during YCP processing at 45∘C at an initial pH of 11.7 or
higher. Processing of cells at an initial pH of 11.5, however,
producing 6-7% glucan exposure, allowed 30–50% preserva-
tion of fluorescence in cells expressing free GFP, U65-GFP,
or U76L-GFP. U65-GFP remains visible as a single aggregate
(Figure 5(c)), much like that present before YCP processing
(Figure 5(b)). 8% of free GFP and 2–4% of U65-GFP or
U76L-GFP fluorescence were released during processing.
SDS-PAGE analysis of the proteins released showed only free
GFP, presumably cleaved from the scaffolded GFP during the
18–20-hour period of galactose-induced expression. While
a subsequent wash with 1% Triton X100 in PBS + 1% 𝛽-
mercaptoethanol released almost all of the residual free
GFP, no additional U65-GFP or U76L-GFP fluorescence was
released. The U65 and U76L scaffolds, therefore, effectively
retained linked GFP during YCP processing at pH 11.5.
3.5. Loss of Surface Mannan in YCPs and Glucan Expo-
sure Revealed by 3T3-D1 Cell Uptake. Phagocytosis of YCPs
by 3T3 cells expressing the dectin-1 𝛽-1,3-glucan receptor
10 Journal of Immunology Research
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Figure 9: SDS-PAGE of proteins from cells and YCPs expressing
U65-GFP (34.1 kDa, arrow). For each set, the first lane shows total
proteins, the second is 16,000×g pellet, and the third is 16,000×g
supernatant. Lanes 1–3, cells. Lanes 4–6, YCPs made by ficin
hydrolysis. Lanes 7–9, YCPs made by hydrolysis at 45∘C, pH 11.5 to
11.3.
(3T3-D1 cells), surrogate APCs, is a much less sensitive but
functionally more relevant test of glucan exposure than anti-
glucan antibody binding. Against a high 25% background for
untreated cells, uptake of YGMP (positive controls for high
glucan exposure) and YCPs with 14% glucan exposure was
90–95%, and uptake of YCPs with 10% glucan exposure was
about 90%.Uptakewas reduced to 80–85% inYCPs processed
at pH 11.5 with 6-7% glucan exposure and to 70–75% in
ficin-treated YCPs (see below) with 5-6% exposure. Mannan
loss under standard YCP processing conditions was assessed
by staining with Alexa Fluor 488-labeled Concanavalin A, a
lectin that selectively binds to mannan. Binding was reduced
by 38% after 10min and 45% after 15min, indicating loss of a
large fraction of surface-accessible mannoprotein.
3.6. Use of Protease for Mannoprotein Removal and YCP
Production. Hydrolysis of PAP1502 cells for 30min at 37∘C
with 2, 4, or 8mg/mL ficin resulted in increasing glucan
exposure. A wash at 23∘C with 20mMNaOH at pH ∼12 then
killed and sterilized the cells and exposed additional glucan,
but membranes apparently remained intact since GFP fluo-
rescencewas unchanged and internal yeast proteins remained
in the 16,000×g supernatant after breakage (Figure 9, Lane
6). U65-GFP remained in an aggregate, mostly found in the
16,000×g pellet (Lane 5). Maximal glucan exposure, after
8mg/mL ficin hydrolysis, was 5-6% of GP levels. Only yeast
proteins less than about 30 kDawere eluted bywashes of ficin-
treated YCPs with PBS + 1% Triton X100, 0.1% sarkosyl, and
1% 𝛽-mercaptoethanol (not shown).Thus, the porosity of the
exposed glucan remained severely compromised by residual
mannan and a single ficin treatment failed to render cell walls
sufficiently permeable for effective removal of yeast proteins.
3.7. Mouse Responses to a U76L-ApoA1 YCP Vaccine. Four
C57BL/6 mice were vaccinated subcutaneously with 2 × 108
U76L-ApoA1 YCPs in which ApoA1 represented about 8% of
total protein (Figure 6(a)), and glucan exposure was about
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Figure 10: Anti-ApoA1 IgG ELISA titers after subcutaneous YCP-
U76L-ApoA1 vaccination. YCPs containing about 90 𝜇g ApoA1 were
administered to four mice on days 0, 14, 28, and 42. Bleeds were on
days 13, 27, 41, and 55.
14% that of GPs. Doses contained about 90 𝜇g ApoA1 and
1.2mg yeast proteins. Bleeds weremade after 13 days and sub-
sequent doses were administered a day later. IgG responses
to ApoA1 determined by ELISA (Figure 10) increased nearly
exponentially for three doses and averaged 400,000 recipro-
cal titer after the fourth dose. IgG responses to total yeast
proteins increased in parallel and were about 20% of ApoA1
responses (not shown). ELISA responses using wells coated
with 0.1𝜇g U76L-GFP, reflecting response to the U76L scaf-
fold, were less than 1% of responses to ApoA1 (not shown).
3.8. Dependence of Mouse Responses to U65-GFP YCPs on
Glucan Exposure and Dose. Cells expressing the U65-GFP
fusion protein at 8% of total protein were converted to YCPs
by extraction at 45∘C at either pH of 11.9–11.6, 11.6–11.4, or
11.5 to 11.3, or by hydrolysis with 8mg/mL ficin. Glucan
exposures were 15, 10, 7, and 6% of GPs, respectively. The pH
11.9 vaccine was tested at two dose levels, 1x and 4x the dose
used for all other vaccine formulations. Groups of five mice
were vaccinated subcutaneously at two-week intervals. Doses
contained about 1.2mg total protein and 90 𝜇g GFP, except
for the 4x group. Average GFP-specific IgG titers are shown
in Figure 11. Variance between titers for the four mice at each
point was no more than 16 fold. A 4x dose of pH 11.9 YCPs
elicited the strongest average responses (upper line). Bleed 4
titers were uniformly at least 106. A 1x dose produced a 5-
fold weaker response. YCPs extracted at pH 11.6 with 10%
glucan exposure were of nearly comparable efficacy (open
circles). YCPs extracted at pH 11.5 or by treatment with ficin
(triangles), with 6-7% glucan exposure, were about 10-fold
less effective than those processed at pH 11.9 or 11.6.
3.9. Expression of MPyV VP1 and VP1-GFP Fusions. MPyV
strain BG (previously identified as strain A2) has been
extensively used for analysis of immune responses in mice
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Figure 11: Average anti-GFP IgG ELISA titers after subcutaneous
YCP-U65-GFP vaccination. Grey triangles: mice vaccinated with
YCPs from ficin-treated cells. YCPs from cells processed at pH 11.5
gave very similar data. Open circles: mice vaccinated with YCPs
from cells processed at pH 11.6. Mice vaccinated with YCPs from
cells processed at pH 11.9 gave very similar data.The upper line,mice
vaccinated with 4x doses of pH 11.9 YCPs.
[27]. The VP1 major capsid protein gene was cloned in pB4
by PCR using a virus stock as template. Following expression
in strain CRY1, Western blots using polyclonal mouse serum
raised against MPyV showed the predicted 42 kDamonomer
VP1 and 200 kDa pentamer VP1 bands. These bands were
completely retained during YCP processing for up to 16min
at 45∘C, at pH 11.9 to 11.7 (not shown). GFP was fused
independently to the N- or C-terminus of VP1. Optimal
expression levels of both were 30% of total protein, as shown
for the 70 kDa VP1-GFP band in Figure 5(a), Lane 1, and
Figure 12, Lane 1. As would be expected for VLPs, most
of the VP1-GFP was in the 16,000×g, 25min pellet from
the 3,000×g supernatant (Figure 12, Lane 2), rather than
in the supernatant (Lane 3). Following YCP processing, all
VP1-GFP and yeast proteins remained in the YCPs (Lane
4) and, after breakage, all proteins were retained in the
16,000×g pellet (Lane 5), apparently as a common aggregate.
A very little amount remained soluble (Lane 6). VP1-GFPwas
enriched from cells broken in the presence of octyl glucoside;
after two rounds of differential centrifugation, SDS-PAGE
analysis showed purity exceeding 95% (not shown).Negative-
stained electron microscopy showed abundant and uniform
80–90 nm diameter particles (Figure 7(a)). VP1 monomers
are 50 kDa and their formation involves interaction of N-
andC-termini [17], presumably precluded in theGFP fusions.
These particles appear to be discrete VLP-like VP1 aggregates,
probably with surface GFP decoration.
3.10. Antibody Responses to Oral and Subcutaneous Vaccina-
tion with YCP-VP1-GFP. YCPs made from cells expressing
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Figure 12: SDS-PAGE of proteins from cells (Lanes 1–3) and
YCPs (Lanes 4–6) expressing VP1-GFP (70 kDa, arrow, 12% of total
protein). Lanes 1 and 4, total proteins. Lanes 2 and 5, 16,000×g pellet.
Lanes 3 and 6, 16,000×g supernatant. M: marker proteins.
VP1-GFP at 12% of total protein were administered orally
or subcutaneously to compare the efficacy of these two
common routes of vaccination in protection against MPyV
infection. Group A mice were vaccinated subcutaneously
with YCPs containing 96𝜇g VPI-GFP fusion protein and
received four boosts at 14-day intervals. As described for oral
starch microparticle vaccines [24], Groups B and C mice
were vaccinated orally on three consecutive days with YCPs
containing, respectively, about 400 and 960 𝜇g VPI-GFP
fusion protein, a total of 12.5 and 30 times the subcutaneous
dose. Group D mice were unvaccinated controls. Bleeds for
analysis of antibody responses were made on the day prior
to each vaccine boost and 14 days after the final doses.
Stool was collected for analysis of IgA production on day 56
before final boost 4. Finally, to test in vivo protection against
MPyV infection, mice were infected intraperitoneally with
106 pfu/mouse on day 71.
Anti-VP1 IgG responses were easily detectable on day 28
and the IgG titers approximately doubled after each dose
(Table 1), averaging 12,000 on day 71 (Figure 13). Reponses
to oral doses were easily detectable on day 42 and also
approximately doubled after each later dose (Table 1). The
lower dose produced titers about 10% of those produced
by subcutaneous vaccination. The high dose responses were
about twofold higher, averaging 20% of those elicited by
subcutaneous dosage (Figure 13).Threemice in the high dose
oral group died shortly after administration of the initial dose,
most likely caused by trauma associatedwith the high volume
gavage, leaving only two. IgG responses to GFP following
subcutaneous dosage were first detectable at day 14 and were
about twice those to VP1 at all later time points, showing a
similar doubling with subsequent boosts to an average titer of
25,000 on day 71 (Table 2, Figure 13). GFP-specific responses
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Table 1: Anti-VP1 IgG titers, defined as reciprocals of dilutions giving a response twofold above background.
Vaccine dosage Bleed 1 Bleed 2 Bleed 3 Bleed 4 Bleed 5
(A) Subcutaneous <200 400–800 800–6400 1600–6400 3200–51200
Average <200 650 2,800 5,600 12,000
(B) Low dose oral <200 <200 200–400 400–1600 200–3200
Average <200 <200 320 800 960
(C) High dose oral <200 <200 200–400 800–1600 800–3200
Average <200 <200 350 1200 2000
Table 2: Anti-GFP IgG titers, defined as reciprocals of dilutions giving a response twofold above background.
Vaccine dosage Bleed 1 Bleed 2 Bleed 3 Bleed 4 Bleed 5
(A) Subcutaneous 400–1600 800–6,400 3,200–12,8000 1,600–25,600 3,400–102,000
Average 800 3,000 6,000 10,000 25,000
(B) Low dose oral <200 200–800 400–6400 400–3200 200–3200
Average <200 400 2200 1200 1600
(C) High dose oral <200 200–800 200–12,800 400–12,800 400–12,800
Average <200 500 3,500 6,700 6,700
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Figure 13: VP1-specific (left) and GFP-specific (right) IgG titers
(ELISA) in sera from bleed 5 in mice vaccinated with VP1-GFP
YCPs. Vaccine was administered orally (PO) at lower (3x 400 𝜇g
VP1-GFP) and higher (3x 960𝜇gVP1-GFP) doses or subcutaneously
(SQ) at a 96 𝜇g dose. Control (Ctrl) mice were not vaccinated. Red
lines indicate mean values.
to oral doses were detectable on day 28. Responses to oral
doses were two- to fourfold higher than responses to VP1, as
shown for day 71 data (Table 2, Figure 13). IgG2B responses
to VP1 and GFP were very similar (not shown).
The sum total of IgG responses to themany yeast proteins
that constituted 88%of the total proteins in theYCP-VP1-GFP
preparation was about twice those to VP1 and similar to anti-
GFP responses.Western blots using sera from bleed 5 of mice
immunized subcutaneously with VP1-GFP YCPs, against
total proteins from strain PAP1502 yeast cells expressing
VP1-GFP, showed responses to multiple unidentified yeast
proteins, predominantly species ∼60 kDa and higher (not
shown). The most prominent band apparently corresponded
to VP1-GFP (70 kDa). Responses to mannoproteins, which
migrate as unresolved species >100 kDa, were relatively weak.
Anti-GFP IgA in stool on day 56 was undetectable
after subcutaneous or lower dose oral vaccination and only
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Figure 14: IgA responses to VP1 and GFP in stools at day 56. Mouse
groups are as described in Figure 13. Red lines indicate mean values.
detectable at dilution >8 in one mouse after higher dose
oral vaccination (Figure 14). Anti-VP1 IgA was undetectable
after subcutaneous vaccination, but the response to oral
vaccination was >100 at either dose level in 5 of 7 mice
(Figure 14). Thus, oral YCP-GFP-VP1 vaccination elicited
mucosal IgA antibody responses preferentially to VP1.
3.11. The YCP-VP1 Vaccine Protects Mice against MPyV Infec-
tion. While MPyV infection in immunodeficient mice can
be lethal, in immunocompetent mice, infection follows a
predictable, self-limiting course [27, 28]. Virus replicates
rapidly in multiple organs, resulting in peak viral loads on
days 5-6 after infection. After this time, an adaptive immune
response initiates viral clearance leading to reduction of
the virus load, but lifelong low levels of PyV persistence
remain. In mice immunized with YCP-VP1-GFP, antiviral
serum antibodies and VP1-specific memory T and B cells are
predicted to reduce the peak virus load following challenge
with live MPyV. Protection against MPyV infection in these
micewas assessed bymeasuring viralDNAgenome copies/𝜇g
organ DNA 5 days after MPyV infection, in comparison with
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Figure 15: Viral load expressed as MPyV DNA genome levels in
organs of YCP-VP1-GFP immunized and unimmunized (Ctrl) mice
5 days after MPyV infection. Mouse groups are as described in
Figure 13. Red lines indicate the mean values.
MPyV-infected, unimmunized mice. qPCR measurements
of MPyV genome copies correlate with measurements of
infectious virus load in organs by plaque assays [29].
Mice were infected intraperitoneally 15 days after the fifth
vaccine dosage, one day after bleed 5, and were sacrificed 5
days later. Viral load (Figure 15) was assayed by measuring
viral genome copies in spleen and liver tissues. In spleen,
viral genome copies/𝜇g DNA in the unvaccinated controls
ranged from 2.6 × 106 to 9.3 × 106 (mean 5.3 × 106). This was
reduced in subcutaneously vaccinated mice to between 3,600
and 101,000 (mean 28,600) and in orally vaccinated mice to
8,000 to 160,000 (lower dose, mean 73,000) and 23,000 to
91,000 (higher dose, mean 57,000). Reductions in spleen viral
load after both subcutaneous and oral immunization were
statistically significant (𝑝 = 0.03 and 𝑝 = 0.035, resp.). The
viral load in liver tissues was 200-fold lower than in spleen,
12,600 to 31,900 in the control unvaccinated mice (mean
24,100) and <20 to 3,700 in the subcutaneously vaccinated
mice (mean 970). In the orally vaccinated mice, half of which
had no detectable viral transcripts, viral load at low dose was
<20 to 570 (mean 178) and at the high dose was <20 to 820
(mean 410). Thus, both subcutaneous and oral vaccination
withVP1-GFPYCPs reduced spleen and liver viral replication
levels by at least two logs.
4. Discussion
Glucan particle (GP) (3) and Yeast Cell Particle (YCP)
vaccines provide novel vaccine antigen-adjuvant delivery
systems with the potential for improved vaccine efficacy
and reduced antigen dose. Processing of antigen-containing
yeast cells into YCP vaccines requires removal of surface
mannoproteins, exposing the 𝛽-1,3-glucan to promote effi-
cient glucan receptor-mediated phagocytosis by APCs [4].
Most of the abundant and dominant yeast cell wall epitopes
[10] should be concomitantly removed. As the glucan shell
is highly permeable, we anticipated that retention of soluble
antigens during YCP processing would require anchoring to
cytoplasmic aggregates. This was demonstrated for residual
fluorescent, scaffold-free GFP in YCPs processed at pH 11.5,
and is likely to be essential for YCPs processed by the standard
pH 11.9 procedure if the antigens are small proteins or peptide
fragments. However, a scaffold is probably unnecessary at pH
11.9 for larger antigens, since such proteins are converted to
a denatured aggregate. If YCP processing by ficin treatment,
where native protein folds are preserved, can be improved to
achieve the >10% glucan exposure required for optimal APC
interaction, this would potentially allow nonionic detergent
elution of soluble yeast proteins and a scaffold would be
essential for antigen retention.
Virus-like particles formed in yeast by self-assembly of
MPyV VP1 viral capsids [17] are effective GFP scaffolds.
IgG responses to the VP1 component of the VP1-GFP vac-
cine were about half of those to GFP. The much smaller
7.2 kDa U65 self-assembling peptide was predicted to be
compatible with any linked antigen and to induce much
weaker competing antiscaffold immune responses. U76L
(9.3 kDa), with 11 additional Ure2p residues and a flexible
linker L, was designed as a potentially more stable scaffold,
presumably permissive of independent folding of any linked
antigen. U65- and U76L-GFP and ApoA1 fusions were highly
expressed and formed large aggregates found in 16,000×g
pellets from broken cells and the GFP fusions were readily
visualized in intact cells and pH 11.5 YCPs. MHCII binding
predictions in C57BL/6 mice for both scaffolds are relatively
weak [14, 15], and while responses to the U76L and U65
scaffolds were not independently tested, responses to U76L-
GFP (which includes the U65 scaffold) in mice vaccinated
with U76L-ApoA1 were less than 1% of responses to the
ApoA1 antigen.
U76L-ApoA1 and U65-GFP pH 11.9 YCP vaccines were
highly effective in mice by subcutaneous administration. IgG
responses to four doses of U76L-ApoA1 YCPs approached
106 reciprocal dilution titer. Responses to U65-GFP YCPs
were similar, while antibody responses to the 12-fold excess of
total yeast proteins were about 5-fold weaker. The dominant
immune responses to the ApoA1 and GFP antigens presum-
ably result from higher abundance and polymeric association
with the peptide scaffolds. U65-GFPYCP vaccines with about
10% glucan exposure were as effective as those with 14 or
20% exposure; however, YCPs with only 6-7% exposure,
whether produced by hydrolysis at lower pH or by ficin
treatment, were 5–10-fold less effective. Glucan exposure
below 10%, therefore, resulted in proportionately reduced
vaccine efficacy, implying that its principal determinant is
interaction with APC glucan receptors, as reflected in 3T3-
D1 cell uptake efficiency. While U65 and U76L fusions
behaved very similarly in mice, expression of U65-fusions
was consistently 10 to 15% higher than equivalent U76L
fusions, and no evidence for differences in folding or stability
of U65- and U76L-GFP fusions was observed in cells, during
YCP production or in subcellular fractions. The simpler U65
scaffold, therefore, appears to be superior.
Parenteral administration of the purified MPyV VP1
capsid protein elicited IgG antibodies in mice [27, 28] and
provided partial protection upon MPyV challenge, reducing
peak virus load [29]. Hamster PyV (HaPyV) VLPs are
also known to be good immunogens and are used in a
recombinant form to generate antibody responses to a variety
of antigens [18]. Here, we test the ability of YCP-VP1-GFP
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oral vaccination in mice to protect against systemic MPyV
infection.The utility of GPs in subcutaneous delivery of puri-
fied antigens is well established [3]. Parenteral vaccinations,
however, often fail to generate the effective mucosal immune
responses required to combat common intestinal (and other
mucosal) infections, and development of an effective oral
vaccination route would be a major advance, particularly in
developing countries [30]. Oral vaccination may also elicit
serum IgG responses, providing protection against a broad
range of infections, and an oral viral capsid-expressing yeast
vaccine has been shown to elicit neutralizing IgG in mice,
superior to purified capsid antigen [31]. An orally adminis-
tered YCP-VP1-GFP vaccine elicited VP1-specific intestinal
IgA and serum IgG responses and we observed reduction
in MPyV load in liver and spleen tissues by 98-99% after
systemic (intraperitoneal) challenge of the vaccinated mice
with live virus. Peak levels at day 5 after infection were well
below the lifelong levels of viral persistence seen in immune-
competent mice following infection [29]. While multiple oral
doses were administered before protection was tested, this
demonstration of effective protection against systemic viral
infection is clearly promising, especially for livestock, where
use of YCPs inmultiple doses as a feed supplement is possible.
Selective removal of yeast proteins from YCPs would
potentially prevent sensitization of vaccine recipients to
dietary yeast [12]. Processing at high pH produces YCPs
with denatured and aggregated internal proteins, preventing
selective elution. In YCPs produced by ficin treatment, all
internal proteins apparently remained in their native state,
potentially allowing responses to topological epitopes and
facilitating selective elution of yeast proteins. This, however,
was not achieved after a single ficin treatment. More vigorous
proteolysis conditions may increase glucan exposure to the
10% required for optimal vaccine function while allowing
removal of yeast proteins soluble in nonionic detergents.
Several reports describe testing of whole recombinant
antigen-expressing yeast cells, retaining all of their internal
proteins and mannoproteins, as vaccines. Heat-killed yeast
expressing carcinoembryonic antigen (CEA), administered
to patients with metastatic, CEA-expressing carcinomas, was
well tolerated [32]. In mouse models, yeast expressing HCV
NS3-Core fusion protein induced antigen-specific cytotoxic
T cell responses that resulted in eradication of circulating
cells expressing the antigen [33, 34], and yeast expressing
mutant BCR-ABL oncogene protein, used as a subcutaneous
vaccine, eliminated leukemia cells expressing this mutant
protein [35]. Recombinant yeast has also been used in oral
vaccines intended for livestock use [8]. Most definitively, oral
vaccination with heat-killed K. lactis or P. pastoris expressing
infectious bursal disease virus VP2 capsid elicited protective
responses in chickens, preventing mortality and reducing
lesions [12, 36].
5. Conclusion
YCP vaccines expressing viral capsid VLPs, scaffolded anti-
gens or, potentially, scaffolded peptide epitopes, can be
produced rapidly, should be easily stored, and are highly
effective inmice, eliciting strong IgG responses and providing
protection against a polyoma virus challenge by either subcu-
taneous or oral dosage. While current formulations may not
be suitable for human use, they have clear potential for use in
feed animal vaccines.
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